A Phase 2a, open-label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)

Project: Other project

Project Details

StatusFinished
Effective start/end date1/1/001/1/00